Compare General Mills, Inc. (GIS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Summit Therapeutics Inc — how do they compare? General Mills, Inc. trades at $32.3 (market cap $17.43B), while Summit Therapeutics Inc trades at $17.54 (market cap $13.71B). The key difference: General Mills, Inc. is the larger of the two by market cap, and General Mills, Inc. pays a 7.49% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Summit Therapeutics Inc for 16 Days on average.
| GIS | SMMT | |
|---|---|---|
Market Cap | $17.43B | $13.71B |
Volume | 16,554,362 | 6,173,057 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $26.38 |
52-Week Low | $31.67 | $12.43 |
Typical Hold Time | 106 Days | 16 Days |
Enterprise Value | $30.61B | $13.04B |
Dividend Yield | 7.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.09, up 1.01% with mixed technical signals showing bearish moving averages but neutral oscillators. The company faces fundamental challenges with a negative net income margin of -4.89% and ROE of -10.55% for 2026, though it maintains strong operating cash flow of $2.92B in 2025. Recent leadership transition to Dana McNabb as CEO and a $3B cost-saving initiative aim to stabilize performance amid declining revenues.
The stock presents a value opportunity with a low P/E of 9.23 and a 7.6% upside to the $36 consensus target, supported by a reliable dividend. However, risks include persistent margin pressures, high debt levels at 45% of assets, and competitive headwinds in the packaged foods sector. Analyst sentiment is cautious with 61% hold ratings, reflecting uncertainty around the turnaround strategy's execution.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
